|
1
|
Hessler M, Jalilian E, Xu Q, Reddy S, Horton L, Elkin K, Manwar R, Tsoukas M, Mehregan D and Avanaki K: Melanoma biomarkers and their potential application for in vivo diagnostic imaging modalities. Int J Mol Sci. 21(9583)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Forsea AM: Melanoma epidemiology and early detection in Europe: Diversity and disparities. Dermatol Pract Concept. 10(e2020033)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shellenberger R, Nabhan M and Kakaraparthi S: Melanoma screening: A plan for improving early detection. Ann Med. 48:142–148. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mandalà M and Massi D: Tissue prognostic biomarkers in primary cutaneous melanoma. Virchows Arch. 464:265–281. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Romaine ST, Wells-Jordan P, de Haro T, Dave-Thakrar A, North J, Pringle JH and Saldanha G: A small multimarker panel using simple immunohistochemistry methods is an adjunct to stage for cutaneous melanoma prognosis. Melanoma Res. 26:580–587. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bolognia J, Schaffer J and Cerroni L (eds): Dermatology. Elsevier, Amsterdam, 2018.
|
|
7
|
Bastian BC: The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 9:239–271. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Elder DE, Massi D, Scolyer RA and Willemze R (eds): WHO Classification of Skin Tumours, WHO, 2018.
|
|
9
|
Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP and Thompson JF: Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 30:2678–2683. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fortes C, Mastroeni S, Mannooranparampil TJ, Passarelli F, Zappala A, Annessi G, Marino C, Caggiati A, Russo N and Michelozzi P: Tumor-infiltrating lymphocytes predict cutaneous melanoma survival. Melanoma Res. 25:306–311. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Park CK and Kim SK: Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma. Oncotarget. 8:14759–14769. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE and Schenk M: Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol. 11(2105)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Dougan M, Dranoff G and Dougan SK: Cancer immunotherapy: Beyond checkpoint blockade. Annu Rev Cancer Biol. 3:55–75. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Havel JJ, Chowell D and Chan TA: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 19:133–150. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ribas A and Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science. 359:1350–1255. 2015.
|
|
16
|
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 161:1681–1696. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ny L, Hernberg M, Nyakas M, Koivunen J, Oddershede L, Yoon M, Wang X, Guyot P and Geisler J: BRAF mutational status as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis. Acta Oncol. 59:833–844. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J and Lundeberg J: NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing. Melanoma Res. 6:471–478. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Eigentler T, Assi Z, Hassel JC, Heinzerling L, Starz H, Berneburg M, Bauer J and Garbe C: Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. Oncotarget. 7:36130–36137. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tas F and Erturk K: Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients. Neoplasma. 66:631–636. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sun Q, Sun H, Wu N, Cong L and Cong X: Prognostic significance of tumor-infiltrating lymphocyte grade in melanoma: A meta-analysis. Dermatology. 236:481–492. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Clark WH Jr, Elder DE, Guerry D IV, Braitman LE, Trock BJ, Schultz D, Synnestvedt M and Halpernet AC: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 81:1893–1904. 1989.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Barnhill RL, Fine JA, Roush GC and Berwick M: Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 78:427–432. 1996.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tuthill RJ, Unger JM, Liu PY, Flaherty LE and Sondak VK: Southwest Oncology Group. Risk assessment in localized primary cutaneous melanoma: A Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 118:504–511. 2002.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Taylor RC, Patel A, Panageas KS, Busam KJ and Brady MS: Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 25:869–875. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Burton AL, Roach BA, Mays MP, Chen AF, Ginter BA, Vierling AM, Scoggins CR, Martin RC, Stromberg AJ, Hagendoorn L and McMasters KM: Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg. 77:188–192. 2011.PubMed/NCBI
|
|
27
|
Mandala M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, Marchesi L, Poletti P, Bonomi L, Novellino L, et al: Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database. Eur J Cancer. 45:2537–2545. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, et al: Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 31:4252–4259. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P and Cascinelli N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 77:1303–1310. 1996.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I and Darvishian F: Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Hum Pathol. 57:116–125. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tas F and Erturk K: Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma. J Cancer Res Clin Oncol. 147:2721–2729. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lin RL, Wang TJ, Joyce CJ, Mihm MC Jr, Murphy GF, Lian CG and Lin YE: Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas. Melanoma Res. 26:524–527. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Platz A, Egyhazi S, Ringborg U and Hansson J: Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 1:395–405. 2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yaman B, Akalin T and Kandiloğlu G: Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma. Am J Dermatopathol. 37:389–397. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bezić J, Kuret S, Vrbičić B, Smolić J, Borić I, Škifić I, Ledina D and Božić J: Clinicopathological characteristics of BRAF V600E mutated melanomas in the dalmatian region of croatia. Acta Dermatovenerol Croat. 27:225–230. 2019.PubMed/NCBI
|
|
36
|
Spathis A, Katoulis AC, Damaskou V, Liakou AI, Kottaridi C, Leventakou D, Sgouros D, Mamantopoulos A, Rigopoulos D, Karakitsos P and Panayiotides IG: BRAF mutation status in primary, recurrent, and metastatic malignant melanoma and its relation to histopathological parameters. Dermatol Pract Concept. 9:54–62. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kim SY, Kim SN, Hahn HJ, Lee YW, Choe YB and Ahn KJ: Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. J Am Acad Dermatol. 72:1036–1046.e2. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Estrozi B, Machado J, Rodriguez R and Bacchi CE: Clinicopathologic findings and BRAF mutation in cutaneous melanoma in young adults. Appl Immunohistochem Mol Morphol. 22:57–64. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Aksenenko MB, Kirichenko AK and Ruksha TG: Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma. Pathol Res Pract. 211:521–527. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Leslie C, Bowyer SE, White A, Grieu-Iacopetta F, Trevenen M, Iacopetta B, Amanuel B and Millward M: FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor. Pathology. 47:557–563. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Klein S, Mauch C, Brinker K, Noh KW, Knez S, Büttner R, Quaas A and Helbigc D: Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E/K mutated malignant melanomas. Sci Rep. 11(1834)2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Safaee Ardekani G, Jafarnejad SM, Khosravi S, Martinka M, Ho V and Li G: Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Br J Dermatol. 169:320–328. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Nagore E, Requena C, Traves V, Guillen C, Hayward NK, Whiteman DC and Hacker E: Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol. 70:858–862.e1-2. 2014.PubMed/NCBI View Article : Google Scholar
|
